GlobeNewswire News Room·2025-06-09 15:58Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of UroGen Pharma Ltd. securities between July 27, 2023, and May 15, 2025, due to alleged misleading statements regarding the effectiveness of UroGen's lead pipeline product, UGN-102 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that UroGen made false and misleading statements about the ENVISION clinical study, which lacked a concurrent control arm, affecting the demonstration of UGN-102's effectiveness [5]. - It is alleged that UroGen ignored FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading nature of UroGen's positive statements about its business and prospects [5]. Group 2: Participation Information - Investors who purchased UroGen securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].